Evidence map›Paper›PMID 42212161›Full record

ReviewFrontiers in immunology2026

Beyond the usual suspects: rethinking post-stroke immunosuppression.

Laia Ascaso-Vidal, Alba Simats, David Brea

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laia Ascaso-VidalDepartment of Neuroscience and Experimental Therapeutics, Instituto de Investigaciones Biomédicas de Barcelona(IIBB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
Alba SimatsDepartment of Neuroscience and Experimental Therapeutics, Instituto de Investigaciones Biomédicas de Barcelona(IIBB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
David BreaDepartment of Neuroscience and Experimental Therapeutics, Instituto de Investigaciones Biomédicas de Barcelona(IIBB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke extends far beyond the hyperacute vascular event. In addition to the immediate ischemic injury, patients frequently develop systemic complications that significantly influence outcome. Among these, a biphasic immune response has emerged as a central feature: an early inflammatory reaction followed by a state of peripheral immunosuppression. This immunosuppressive phase has been consistently associated with increased susceptibility to post-stroke infections, particularly pneumonia, thereby contributing to morbidity and mortality. Multiple mechanisms have been implicated in the development of stroke-induced immunosuppression, including activation of the autonomic nervous system and the hypothalamic-pituitary-adrenal axis, the release of damage-associated molecular patterns (DAMPs), reprogramming of bone marrow hematopoiesis, and peripheral neutrophil activation with downstream effects on lymphocyte survival. While these pathways are often studied in isolation, accumulating evidence suggests that they may interact within a coordinated neuroimmune network. In this review, we not only summarize the current understanding of the mechanisms underlying post-stroke immunosuppression but also explore how these processes may converge and influence one another. Finally, we discuss the unresolved question of whether this immunosuppressive state represents an adaptive response aimed at protecting the injured brain or a maladaptive bystander consequence of disrupted neuroimmune homeostasis.

Indexed as

Immune ToleranceIschemic StrokeStrokeAnimalsHumansNeuroimmunomodulationischemic strokelymphopeniaperipheral immunodepressionpost-stroke infectionsstroke-induced immunosuppression

Identifiers

PMID42212161
PMCPMC13212228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.